EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Phyto Extractions Inc (XTXXF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Phyto Extractions Inc $0.01, price $0.01, upside +0.6%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

PE Phyto Extractions Inc logo Thin data Sep 24, 2026

Phyto Extractions Inc

XTXXF · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.0070 · Fairly valued (+0.6%)
!Quality 47/100
!Mixed Growth (revenue 3y +64.0 %/yr)
!Loss-making · -85.9% net margin (TTM)
✓Negative equity (buybacks among others) · generates free cash flow
!Trails peers (2/7)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
Watch Phyto Extractions Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$11.69 $0.0070 Fair Value $0.0070 Jul 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.0070 – $11.69 · fair‑value band $0.0068 – $0.0072 · the $0.0070 price screens below the $0.0070 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Phyto Extractions in your weekly email

Every Wednesday you see whether Phyto Extractions is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Adastra Holdings Ltd. extracts and processes cannabis for recreational and medical markets in Canada. The company offers vape pens, wax, resin, infused pre-rolls, diamonds, and shatters under the Endgame brand. It also provides consulting and white label manufacturing. The company was formerly knowns as Phyto Extractions Inc.

Show more

Adastra Holdings Ltd. extracts and processes cannabis for recreational and medical markets in Canada. The company offers vape pens, wax, resin, infused pre-rolls, diamonds, and shatters under the Endgame brand. It also provides consulting and white label manufacturing. The company was formerly knowns as Phyto Extractions Inc. and changed its name to Adastra Holdings Ltd. in September 2021. Adastra Holdings Ltd. is headquartered in Langley, Canada.

Stock analysis

Phyto Extractions Inc (XTXXF) currently trades at $0.0070, while our model-based Fair Value estimate is $0.0070, so the stock looks roughly fairly valued today (gap 0.6%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $0.0070 per share, and 3 of the 10 models we run sit above the $0.0070 price.

Bear case: the Growth DCF group reads lowest at $0.0049, and 7 of the 10 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.0068 (bear) to $0.0072 (bull), the price of $0.0070 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Phyto Extractions Inc reported revenue of C$24.8M in FY2024 versus C$2.5M in FY2020, a compound +77.6%/yr. Reported net income was −C$13.2M in FY2024.

Key figures

Market cap $39.2K · EPS (TTM) $−1.83 · Net margin −53.3% · Return on equity −230% · Return on assets (EBIT) −14.7% · Operating margin −7.3% · Revenue (TTM) C$16.9M · Revenue growth (YoY) −33.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 65% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 1%, XTXXF screens cheaper than that median.

Fair Value models

Bear $0.0068 Fair Value $0.0070 Bull $0.0072
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $0.0077 $0.0123 $0.0266 70
Growth DCF $0.0072 $0.0144 $0.0260 70
5Y EBITDA Exit $0.0024 $0.0035 $0.0057 69
All 10 models by family
DCF Models
FCF DCF $0.0077 $0.0123 $0.0266 70
5Y Revenue Exit $0.0027 $0.0042 $0.0073 66
5Y EBITDA Exit $0.0024 $0.0035 $0.0057 69
10Y Revenue Exit $0.0042 $0.0078 $0.0093 63
10Y EBITDA Exit $0.0040 $0.0070 $0.0114 62
Multiples
EV/EBITDA $0.0002 $0.0005 $0.0008 62
EV/Revenue $0.0006 $0.0011 $0.0017 51
Asset-Based
NCAV (Graham) $0.0003 $0.0003 $0.0005 54
Growth DCF
Growth DCF $0.0072 $0.0144 $0.0260 70
Rev-Margin DCF $0.0030 $0.0049 $0.0091 65

Open the full fair value analysis →

Notify me when XTXXF reaches fair value

Put XTXXF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 47/100

Of which business quality 45 · Market factors (momentum, volatility) 22

Profitability 36
Margins and returns on capital today
Quality Growth 49
Are margins and returns improving?
Cashflow 24
Earnings quality: real cash, not paper profit
Fin. Strength 6
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 17
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 54/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−286.5% (2020) → −3.9% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

Watch XTXXF, get fair value alerts →

Compare Phyto Extractions Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 621 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside +0.6% · Above median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −6.5% · Bottom 25%
Net margin (TTM) −85.9% · Bottom 25%
Operating margin (TTM) −7.3% · Bottom 25%
Growth and dividend
Revenue growth −33.2% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/FCF 0.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)34 · sector 15
FUTURE (revenue growth)0 · sector 18
PAST (return on equity)0 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €135.00 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.86 $11.40 −40%
Teva Pharmaceutical Industries Limited TEVA $39.19 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $71.05 $110.50 +56%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Phyto Extractions Inc · Fair Value
$0.0070 +1%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Phyto Extractions Inc Fair Value". https://www.fairvalue-calculator.com/stock/XTXXF

Frequently asked questions

Is Phyto Extractions Inc (XTXXF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.0070 versus a price of $0.0070, about +1% upside (fairly valued).
What is the fair value of XTXXF?
Our model-based fair value for Phyto Extractions Inc is $0.0070 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.0070.
What is the quality score of XTXXF?
Phyto Extractions Inc has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Phyto Extractions Inc (XTXXF)?
Our model-based price target is the fair value of $0.0070 (as of Sep 24, 2026) from 10 valuation models. Cautious scenario $0.0068, optimistic scenario $0.0072. It is a calculation from audited fundamentals, not an analyst target.
What is the Phyto Extractions Inc stock forecast for 2026?
Our models put fair value at $0.0070, about +1% upside versus a price of $0.0070 (fairly valued). Cautious scenario $0.0068, optimistic scenario $0.0072. The calculation is refreshed regularly with new filings.
What is the revenue of Phyto Extractions Inc (XTXXF)?
Phyto Extractions Inc reported trailing-twelve-month revenue of about C$16.9M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Phyto Extractions Inc (XTXXF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Phyto Extractions Inc it is $0.0070 per share (as of Sep 24, 2026), against a price of $0.0070. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Phyto Extractions Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, XTXXF trades below its calculated fair value: price $0.0070, fair value $0.0070, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of XTXXF?
No. The price is what the market pays today ($0.0070); the fair value is what the company's own numbers justify ($0.0070). For Phyto Extractions Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Phyto Extractions Inc worth?
The market values Phyto Extractions Inc at about $39.2K (market capitalisation, as of Sep 24, 2026). Per share that is $0.0070; our models calculate a fair value of $0.0070 per share.
What do the bullish and bearish scenarios say about XTXXF?
Our models span a range for Phyto Extractions Inc: cautious scenario $0.0068, base $0.0070, optimistic $0.0072 per share (as of Sep 24, 2026, price $0.0070). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Phyto Extractions Inc (XTXXF)?
Balance-sheet figures for Phyto Extractions Inc (as of Sep 24, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is XTXXF from its 52-week high?
Phyto Extractions Inc trades at $0.0070, about 65% below its 52-week high of $0.0200 and at the low of $0.0070 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0070 is for.
Which stocks are comparable to Phyto Extractions Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Phyto Extractions Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $0.0070, calculated fair value $0.0070 (+1%), Quality Score 47/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of XTXXF calculated?
We run Phyto Extractions Inc through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0070, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Phyto Extractions Inc currently trades 1 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Phyto Extractions Inc (XTXXF)?
The closing price on Sep 25, 2026 was $0.0070. Our model-based fair value is $0.0070, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Phyto Extractions Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0068 to $0.0072), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Phyto Extractions Inc

How large is the market capitalisation of Phyto Extractions Inc (XTXXF)?
The market capitalisation of Phyto Extractions Inc is $39.2K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Phyto Extractions Inc (XTXXF)?
Earnings per share at Phyto Extractions Inc are $−1.83. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Phyto Extractions Inc (XTXXF)?
The net margin of Phyto Extractions Inc is −53.3% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Phyto Extractions Inc (XTXXF)?
The return on equity (ROE) of Phyto Extractions Inc is −230% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Phyto Extractions Inc (XTXXF)?
On an EBIT basis the return on assets of Phyto Extractions Inc is −14.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Phyto Extractions Inc (XTXXF)?
The operating margin of Phyto Extractions Inc is −7.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Phyto Extractions Inc (XTXXF)?
Revenue at Phyto Extractions Inc is growing −33.2% versus a year earlier (3y avg +64.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Phyto Extractions Inc (XTXXF) generate?
The free cash flow of Phyto Extractions Inc is C$410K (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Phyto Extractions Inc (XTXXF) carry?
The net debt of Phyto Extractions Inc is C$2.3M (fiscal year 2024, ≈ 5.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Phyto Extractions Inc in the live analysis

One click puts Phyto Extractions Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.